Summary:
- Boston Scientific (BSX, Financial) faces challenges due to new tariffs affecting medical device imports.
- Analysts predict a potential 17.79% upside with a target price of $116.97.
- GF Value indicates a 22.52% downside from current prices.
Boston Scientific Corp (BSX) finds itself navigating significant hurdles as a result of the recent tariff policies announced by President Trump. The medical device sector, heavily reliant on imports from the EU and China, is hit hard, with import tariffs escalating to 20% and 34%, respectively, creating intricate challenges for companies in this space, including Boston Scientific.
Wall Street Analysts Forecast
According to insights from 29 analysts, the one-year price target for Boston Scientific Corp (BSX, Financial) is set at an average of $116.97. Within this range, the high estimate stands at $130.00, while the low is at $84.11. This average target points towards a potential upside of 17.79% from the current price of $99.30. For more comprehensive projections, please visit our Boston Scientific Corp (BSX) Forecast page.
The consensus recommendation from 34 brokerage firms positions Boston Scientific Corp (BSX, Financial) at an average rating of 1.8, suggesting an "Outperform" status. Our recommendation scale ranges from 1 (Strong Buy) to 5 (Sell), underscoring a favorable outlook from the investment community.
From the perspective of GuruFocus estimates, the GF Value for Boston Scientific Corp (BSX, Financial) in one year's time is anticipated to be $76.94. This estimate reveals a possible downside of 22.52% from the current trading price of $99.30. The GF Value is calculated considering the historical trading multiples, past business growth, and future performance estimates of the company. For further detailed analysis, explore our Boston Scientific Corp (BSX) Summary page.
